Articles

On March 11, 2026, the FDA announced the launch of the FDA Adverse Event Monitoring System (AEMS), a unified platform designed to modernize and streamline the agency’s analysis of adverse event reports.

On February 19, 2026, the FDA approved the combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Sweeping insurance and policy changes are poised to reshape how patients access and maintain coverage across Medicare, the Marketplace, Medicaid, and the Supplemental Nutrition Assistance Program (SNAP).

Imagine you are a healthcare provider seeing a complex patient with symptoms that could point to hundreds of conditions.

Advances in precision medicine and biomarker testing are transforming lung cancer treatment, offering hope through targeted therapies and innovative approaches.

With major reimbursement and coverage changes occurring in 2026, oncology practices are closely watching federal policy developments that could affect everything from prior authorization workflows to drug reimbursement and patient coverage stability.

It started with a bit of blood.

Although biomarker-driven targeted therapies for gastric cancer have advanced significantly, many eligible patients are not receiving these treatments, highlighting the urgent need to overcome barriers such as insufficient biomarker testing and socioeconomic disparities.